The anti-PD-1 antibody + chidamide (50 mg/kg) + celecoxib (50 mg/kg) regimen demonstrated the best antitumor response, with primary tumor eradication in 3 out of 4 mice and 50% survival at day 58 after tumor implantation (SFig. 3). This evidence concerns the gene PDCD1 and neoplasm.